Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 30, 1996

Primary Completion Date

April 30, 2003

Study Completion Date

January 31, 2008

Conditions
Lymphoma
Interventions
DRUG

aminocamptothecin

850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response

Trial Locations (5)

55455

University of Minnesota Cancer Center, Minneapolis

63110

Washington University Barnard Cancer Center, St Louis

20307-5000

Walter Reed Army Medical Center, Washington D.C.

08103

Cooper Cancer Institute, Camden

07503

St. Joseph's Hospital and Medical Center, Paterson

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH